Anxa2 binds to STAT3 and promotes epithelial to mesenchymal transition in breast cancer cells
Metrics: PDF 1697 views | HTML 1681 views | ?
Tong Wang1,*, Jie Yuan1,*, Jie Zhang1, Ran Tian1, Wei Ji1, Yan Zhou1, Yi Yang1, Weijie Song1, Fei Zhang1 and Ruifang Niu1
1 Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, The Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Key Laboratory of Cancer Prevention and Therapy, Tianjin, PR China
* These authors have contributed equally to this work
Ruifang Niu, email:
Fei Zhang, email:
Keywords: Anxa2, breast cancer, epithelial–mesenchymal transition, epidermal growth factor receptor
Received: February 07, 2015 Accepted: August 09, 2015 Published: August 15, 2015
Overexpression of annexin A2 (Anxa2) is correlated with invasion and metastasis in breast cancer cells. In this study, breast cancer patients with upregulated Anxa2 exhibited poor overall and disease-free survival rates. Anxa2 expression was also positively correlated with the expression of epidermal growth factor receptor (EGFR) and epithelial–mesenchymal transition (EMT) markers in breast cancer tissues and cell lines. Moreover, knockdown of Anxa2 impaired EGF-induced EMT, as well as the migration and invasion of breast cancer cells in vitro. Meanwhile, Anxa2 depletion significantly ablated pulmonary metastasis in a severe combined immunodeficiency mouse model of breast cancer. Importantly, Anxa2 reduction inhibited EGF-induced activation of STAT3, which is required for EGF-induced EMT. Anxa2 directly bound to STAT3 and enhanced its transcriptional activity, thereby indicating that Anxa2 promotes EGF-induced EMT in a STAT3-dependent manner. Our findings provide clinical evidence that Anxa2 is a poor prognostic factor for breast cancer and reveal a novel mechanism through which Anxa2 promotes breast cancer metastasis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.